Sanofi's BTK in­hibitor again slows MS pro­gres­sion, but liv­er en­zymes con­tin­ue to be tricky

Sanofi re­leased new Phase 3 da­ta for its BTK in­hibitor tole­bru­ti­nib in non-re­laps­ing sec­ondary pro­gres­sive mul­ti­ple scle­ro­sis (nr­SPMS), show­ing a 31% im­prove­ment in de­lay­ing on­set …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER